Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center

[1] Ofran Y(2016)How I treat acute myeloid leukemia presenting with preexisting comorbidities Blood 28 488-496

[2] Tallman MS(2017)Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia Leukemia 31 1217-1220

[3] Rowe JM(2017)Treatment of Relapsed/Refractory Acute Myeloid Leukemia Curr Treat Options Oncol 18 17-46

[4] Schlenk RF(2018)Epigenetics in Hematological Malignancies Methods Mol Biol 1856 87-101

[5] Frech P(2015)Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia Oncotarget 6 6448-6458

[6] Weber D(2012)Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia J Clin Oncol 30 2670-2677

[7] Bose P(2018)Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia Leuk Lymphoma 59 2570-2579

[8] Vachhani P(2015)The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients Oncotarget 6 33612-33622

[9] Cortes JE(2018)Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines Am J Transl Res 10 2567-2578

[10] Cruz-Rodriguez N(2019)A combination of low-dose decitabine and chidamide resulted in synergistic effects on the proliferation and apoptosis of human myeloid leukerma cell lines Am J Transl Res 11 7644-7655

[1] Ofran Y(2016)How I treat acute myeloid leukemia presenting with preexisting comorbidities Blood 28 488-496

[2] Tallman MS(2017)Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia Leukemia 31 1217-1220

[3] Rowe JM(2017)Treatment of Relapsed/Refractory Acute Myeloid Leukemia Curr Treat Options Oncol 18 17-46

[4] Schlenk RF(2018)Epigenetics in Hematological Malignancies Methods Mol Biol 1856 87-101

[5] Frech P(2015)Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia Oncotarget 6 6448-6458

[6] Weber D(2012)Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia J Clin Oncol 30 2670-2677

[7] Bose P(2018)Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia Leuk Lymphoma 59 2570-2579

[8] Vachhani P(2015)The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients Oncotarget 6 33612-33622

[9] Cortes JE(2018)Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines Am J Transl Res 10 2567-2578

[10] Cruz-Rodriguez N(2019)A combination of low-dose decitabine and chidamide resulted in synergistic effects on the proliferation and apoptosis of human myeloid leukerma cell lines Am J Transl Res 11 7644-7655